文献速递腹部介入USMR

经皮超声/MRI融合导航射频消融治疗复发性亚厘米肝细胞癌:技术可行性与治疗结局

Percutaneous US/MRI Fusion-guided Radiofrequency Ablation for Recurrent Subcentimeter Hepatocellular Carcinoma: Technical Feasibility and Therapeutic Outcomes.
PubMed 文献 · Radiology · 2018-06-19

回顾性研究评估2012年1月至2014年12月186例患者共194次计划性超声检查中,超声/MRI融合导航经皮射频消融治疗新发亚厘米复发性肝细胞癌的可行性与疗效。计划性超声下可行率为65.7%(138/210个病灶),最常见不可行原因为病灶在超声上不明显。125个病灶行消融,技术成功率和疗效均达98.4%,1、2、3年累积局部肿瘤进展率分别为3.6%、5.4%、7.4%,主要并发症率2.5%。

要点

  • 计划性超声下约三分之二(65.7%)的亚厘米复发性肝细胞癌可行超声/MRI融合导航经皮射频消融。
  • 最常见不可行原因是病灶在超声上不明显。
  • 可行病灶消融后技术成功率和疗效均为98.4%,1、2、3年累积局部肿瘤进展率分别为3.6%、5.4%、7.4%。

核心结论

  • 超声/MRI融合导航经皮射频消融对约三分之二的亚厘米复发性肝细胞癌可行,是安全有效的治疗方式。

研究设计与样本

  • 回顾性研究,2012年1月至2014年12月共186例患者(159男、27女,平均年龄61.1岁±10.0)行194次计划性超声检查,评估新发亚厘米复发性肝细胞癌(>5.5 mm且<10 mm、具有典型MRI表现的富血供结节)。

关键影像表现/征象

  • 复发性肝细胞癌定义为>5.5 mm且<10 mm、具有典型MRI表现的富血供结节。
  • 计划性超声下病灶在超声上不明显是射频消融不可行的最常见原因。

诊断标准与关键数值

  • 计划性超声下经皮射频消融可行率为65.7%(138/210个病灶)。
  • 可行病灶中125个行经皮射频消融,技术成功率98.4%(123/125),技术疗效98.4%(123/125)。
  • 累积局部肿瘤进展率1年3.6%、2年5.4%、3年7.4%。
  • 主要并发症率2.5%(3/119)。

临床应用与阅片要点

  • 对亚厘米复发性肝细胞癌,计划性超声可评估经皮射频消融的可行性,病灶超声显像不明显是主要限制。
  • 超声/MRI融合导航有助于对超声不明显的亚厘米复发性肝细胞癌进行经皮射频消融。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

Purpose To evaluate the technical feasibility and therapeutic outcomes of percutaneous US/MRI fusion-guided radiofrequency ablation (RFA) of recurrent subcentimeter-sized hepatocellular carcinomas (HCCs). Materials and Methods For this retrospective study, between January 2012 and December 2014 a total of 194 planning US examinations were performed in 186 patients (159 men and 27 women; mean age, 61.1 years ± 10.0 [standard deviation]) for newly developed subcentimeter recurrent HCCs. These recurrent HCCs were defined as hypervascular nodules (>5.5 mm and <10 mm) with typical MRI findings of HCC. The study assessed how often US/MRI fusion-guided percutaneous RFA was deemed technically feasible at planning US examination (the feasibility rate) and the therapeutic outcomes after RFA, including the rates of technical success, technique efficacy, local tumor progression (LTP), and major complications. Cumulative LTP rates were estimated with the Kaplan-Meier method. Results The feasibility rate of percutaneous RFA at planning US examination was 65.7% (138 of 210 HCCs). The most common reason for RFA infeasibility was that an index tumor was inconspicuous at US. Among 138 subcentimeter HCCs feasible for RFA, 125 lesions underwent percutaneous RFA. The rates of both technical success and technique efficacy were 98.4% (123 of 125). The cumulative LTP rates at 1, 2, and 3 years were 3.6%, 5.4%, and 7.4%, respectively. The major complication rate was 2.5% (three of 119). Conclusion Percutaneous US/MRI fusion-guided radiofrequency ablation (RFA) was feasible in approximately two-thirds of subcentimeter recurrent hepatocellular carcinomas (HCCs). Percutaneous US/MRI fusion-guided RFA is a safe and effective treatment modality for patients with subcentimeter recurrent HCCs.

来源:Radiology,查看原文。版权归原作者所有。

引用

  1. Song KD, Lee MW, Rhim H, et al. Percutaneous US/MRI Fusion-guided Radiofrequency Ablation for Recurrent Subcentimeter Hepatocellular Carcinoma: Technical Feasibility and Therapeutic Outcomes. Radiology. 2018. PMID: 29916771. doi:10.1148/radiol.2018172743

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。